FDA approves Takeda's Mimrylo for rare blood cancer polycythemia vera
Tweet Send to a Friend
Takeda Pharmaceutical (TSE: 4502 / NYSE: TAK) has received U.S. Food and Drug Administration approval for Mimrylo (rusfertide), a treatment ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


